Center-Authored Papers

Filters: Author is Gupta, Shilpa  [Clear All Filters]
2012
Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Buyyounouski MK, Carducci MA, Chang SS, Choueiri TK, Gupta S et al..  2012.  Testicular cancer.. Journal of the National Comprehensive Cancer Network : JNCCN. 10(4):502-35.
2014
Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Derweesh IH, Gupta S et al..  2014.  Kidney cancer, version 2.2014.. Journal of the National Comprehensive Cancer Network : JNCCN. 12(2):175-82. Abstract
2015
Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH et al..  2015.  Kidney cancer, version 3.2015.. Journal of the National Comprehensive Cancer Network : JNCCN. 13(2):151-9. Abstract
Yu EY, Li H, Higano CS, Agarwal N, Pal SK, Alva A, Heath EI, Lam ET, Gupta S, Lilly MB et al..  2015.  SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(14):1601-8. Abstract
2016
Nanda R, Chow LQM, Dees CE, Berger R, Gupta S, Geva R, Pusztai L, Pathiraja K, Aktan G, Cheng JD et al..  2016.  Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(21):2460-7. Abstract
Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B et al..  2016.  Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial.. The Lancet. Oncology. Abstract
Chow LQM, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee S-H et al..  2016.  Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Abstract
2017
Plimack ER, Bellmunt J, Gupta S, Berger R, Chow LQM, Juco J, Lunceford J, Saraf S, Perini RF, O'Donnell PH.  2017.  Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study.. The Lancet. Oncology. Abstract